JP2006225398A - Dental viscous pharmaceutical containing basic fibroblast growth factor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical preparation which contains a basic fibroblast growth factor (bFGF) as an effective ingredient and is effective as a medicine for various periodontal diseases such as periodontal disease. <P>SOLUTION: The viscous preparation for dental comprises a basic fibroblast growth factor (bFGF) as an effective ingredient, and further various thickeners, such as hydroxypropylcellulose as a representative example. A kit for preparing the viscous preparation for dental comprises mixing bFGF, a thickener, an inactive non-toxic additive, and a dissolving liquid. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a viscous viscous preparation containing basic fibroblast growth factor that can be used for the treatment of various periodontal diseases such as periodontal disease.

  bFGF, a basic fibroblast growth factor, was found as a protein that significantly promotes fibroblast proliferation. Thereafter, it not only promotes the proliferation of fibroblasts in vitro, but also has an effect of promoting proliferation, migration and differentiation of various cells such as vascular endothelial cells, vascular smooth muscle cells, and epithelial cells. It has been revealed. It has also been revealed that it has a strong angiogenic action in vivo. Since bFGF has such a pharmacological action, it has been developed as a therapeutic agent for refractory skin ulcer, and has been confirmed to have excellent therapeutic effect and safety in clinical research, and is currently marketed. BFGF also has a useful effect on bone tissue and promotes fracture healing. Furthermore, as a new type of osteogenesis promoter that induces the formation of bone tissue in the administered region, clinical application to various bone diseases requiring bone formation including fractures is expected. bFGF further promotes alveolar bone formation (bone density, alveolar bone area, trabecular area) when administered to periodontal tissue defect sites, and promotes cementum formation and periodontal ligament regeneration on exposed root surfaces. Thus, it has been clarified that periodontal tissue is regenerated with good balance. From this, it is recognized that it is effective in leading to regenerative healing and new adhesion healing, which are the final purpose of periodontal disease treatment. In addition, it is considered useful for the treatment of various periodontal diseases such as restoration of periodontal tissue after extraction and removal of cyst or oral cancer, promotion of colonization of the implant material, and regeneration of dentin deficient by caries. . In particular, adaptation to periodontal disease, which is a chronic tissue defect, is considered (WO95 / 05840).

  On the other hand, considering that bFGF has a strong and diverse pharmacological action, it is desirable to administer it directly only to the affected part that requires the action of bFGF. In order to efficiently apply bFGF to each disease, a suitable formulation design is required. In fact, preparations suitable for diseases such as spray preparations for refractory skin ulcers and gel preparations for bone diseases are performed. However, a useful bFGF preparation that can be directly and efficiently applied to various periodontal diseases such as periodontal disease has not been developed so far.

  On the other hand, pasta, liquid, ointment, gel and the like are generally known as dosage forms for dental preparations. However, bFGF is physicochemically unstable and has a low medicinal dose. Therefore, it is considered that it is difficult to develop pasta and ointment, especially due to restrictions on its dosage form and production conditions. It was done. On the other hand, it has been considered that liquid agents and gels containing bFGF can be developed by preparing preparations at the time of use. In the clinical application of bFGF in the treatment of various periodontal diseases, especially periodontal disease, it is expected to be administered into the gingiva with the expectation of alveolar bone regeneration at the time of flap operation (a technique of opening the gingiva and removing calculus etc.) The However, in the case of administration to the maxillary part, there is a concern that the preparation may not be retained in the affected area for a sufficient time due to dripping and cannot be efficiently administered to the affected area. Therefore, a jelly-like gel preparation can be considered as a preparation that compensates for the drawbacks. A gel preparation is not a preferable dosage form for uniformly applying a low content of a drug to an affected area having various shapes quantitatively. In particular, in the case of a gel preparation, if the base remains in the affected area for a long period of time, it is expected to inhibit tissue repair, and it is also expected that the patient will complain of discomfort as a foreign body. Therefore, the base must be highly functional so that it quickly decomposes or disappears after being held in the affected area for a certain time after administration, but such a base is disadvantageous in that it is expensive. have.

  Therefore, in order to develop bFGF as a therapeutic agent for various periodontal diseases such as periodontal diseases, bFGF is stably retained, low content of bFGF is applied to the affected area having a small volume, and dripping is suppressed. It is desirable that it can be applied uniformly. In addition, it has been desired to develop a dental preparation made of an inexpensive material that can be rapidly decomposed or disappeared after being stored to an extent that does not inhibit tissue repair after application, and can be applied more efficiently.

  As a result of earnest research to solve the above-mentioned problems, the inventors of the present invention formulated bFGF with a thickener capable of maintaining a certain viscosity when made into a solution to obtain a viscous preparation. Discovered that a stable preparation of bFGF can be stably applied to a diseased part of various shapes with a low content of bFGF, and a preparation with excellent local retention can be obtained. It came to do.

  The present invention relates to a viscous dental preparation containing basic fibroblast growth factor (bFGF) as an active ingredient and further containing a thickener.

  In the viscous preparation for dental use of the present invention, by adding a thickener having a certain viscosity, an appropriate viscosity and a local storage property of the viscous preparation are ensured, thereby more reliably administering bFGF to the affected area. Can be.

  The present invention also provides a kit for preparing the dental viscous preparation of the present invention, comprising a bFGF, a thickener, an inert non-toxic additive, if necessary, and a solution, and The invention also relates to a method for preparing a dental viscous formulation, characterized in that bFGF, a thickener and, if necessary, an inert and non-toxic additive are dissolved in a solution. .

  The dental viscous preparation of the present invention is a dental viscous preparation containing bFGF as an active ingredient and further containing a thickener. The viscous preparation here means a preparation having a viscosity of about 20 to 25,000 mPa · s when measured using an E-type viscometer at 25 ° C. The dental viscous preparation of the present invention preferably has a viscosity of about 1,000 to 20,000 mPa · s, particularly preferably about 3,000 to 15,000 mPa · s.

  Examples of bFGF contained in the viscous dental preparation of the present invention include those derived from mammals. Examples of mammals include humans, monkeys, pigs, cows, sheep and horses. From these mammals, bFGF can be obtained by a known method, and bFGF derived from an animal such as bovine bFGF is commercially available as a reagent from several companies.

  Moreover, as this bFGF, what was manufactured by the recombinant DNA technique can also be used. In order to produce bFGF by recombinant DNA technology, for example, the technology described in Japanese Patent Publication 63-500843 can be used. Human bFGF produced by recombinant DNA technology is sold as a reagent, and the generic name: trafermin (genetical recombination) can be preferably used.

  The bFGF concentration of the dental viscous preparation of the present application is preferably about 0.0001 to 20% by weight, more preferably about 0.001 to 10%, based on the total weight of the preparation, considering the effect on periodontal diseases. % By weight, most preferably about 0.01 to 1% by weight.

  The thickener contained in the viscous preparation for dental use of the present invention can exhibit the above-mentioned viscosity (about 20 to 25,000 mPa · s) when it is used as a solution, and adversely affects the stability of bFGF. Any thickening agent that is not adversely affected and is pharmaceutically acceptable can be used at any concentration. Specifically, hydroxypropylcellulose, sodium alginate, propylene glycol ester alginate, carboxyvinyl polymer, carmellose sodium, hyaluronic acid, sodium hyaluronate, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, polyacrylic acid, polyacrylic acid Sodium, polyacrylic acid partial neutralized product, polyvinyl alcohol, methyl cellulose, xanthan gum, chondroitin acid, sodium chondroitin sulfate, and the like can be used. Of these, hydroxypropylcellulose (HPC), sodium hyaluronate, xanthan gum, and sodium chondroitin sulfate can be preferably used in consideration of the effect on bFGF stability, and hydroxypropylcellulose can be particularly preferably used. .

  Besides these thickeners, gum arabic, gum arabic powder, guar gum, glucono-δ-lactone, gelatin, dextran 70, dextrin, tragacanth, tragacanth powder, povidone, water candy, rosin, polyoxyethylene (160) Thickeners such as polyoxypropylene (30) glycol, polyoxyethylene (200) polyoxypropylene glycol (70), and a copolymer of methyl vinyl ether and maleic anhydride can also be used.

  Hydroxypropyl cellulose that can be particularly preferably used as a thickener in the dental viscous preparation of the present invention is a hydroxypropyl ether derivative of cellulose. When the dried product is quantified, hydroxypropyl groups 53.4 to 77 are used. .5% (Japanese Pharmacopoeia 14th revision D) is preferable. When HPC is dissolved in water, it becomes a viscous liquid, but when it is made into an aqueous solution, it is an HPC that exhibits a viscosity of about 20 to 25,000 mPa · s when measured using an E-type viscometer at 25 ° C. For example, HPC having an arbitrary molecular weight can be used at a concentration showing the above viscosity. However, those having a high viscosity at a low concentration and having a molecular weight of about 100,000 to 500,000 can be preferably used, more preferably 110,000 to 400,000. For example, when using HPC having a molecular weight of about 110,000 to 150,000, HPC-M manufactured by Nippon Soda Co., Ltd. is preferably used at a ratio of about 2 to 18% by weight with respect to the whole preparation. More preferably, it can be used at a ratio of about 3 to 10% by weight. In addition, when using HPC having a molecular weight of about 250,000 to 400,000, HPC-H manufactured by Nippon Soda Co., Ltd. is preferably used at a ratio of about 1 to 9% by weight with respect to the whole preparation. More preferably, it can be used at a ratio of about 2 to 6% by weight. As long as the above viscosity can be achieved, HPCs having different molecular weights can be appropriately mixed and used.

  Moreover, also when using sodium hyaluronate, a xanthan gum, and sodium chondroitin sulfate as a thickener, it can be used in the density | concentration of the range which can achieve said viscosity. For example, when sodium hyaluronate is used, a molecular weight of about 600,000 to 900,000 can be used at a concentration of about 1% by weight. When xanthan gum is used, a molecular weight of about 2 million can be used at a concentration of about 1% by weight. Other thickeners can also be used at concentrations in a range where the above viscosity can be achieved.

  The dental viscous preparation of the present invention further includes pharmaceutically acceptable additives such as sugars, pH adjusters, preservatives, chelating agents, emulsifiers, suspending agents, stabilizers, and coloring agents as necessary. Can be included. Examples of the saccharide include sucrose and trehalose, and sucrose can be particularly preferably used. Further, the pH of the dental viscous preparation of the present invention is desirably maintained at about 4.5 to 8, particularly 4.5 to 6.5, and as a pH adjuster for maintaining this pH, Examples include a buffer solution consisting of acid and sodium citrate or acetic acid and sodium acetate. Examples of preservatives and chelating agents include benzalkonium chloride and sodium edetate, respectively.

  The viscous dental preparation of the present invention can be prepared by blending the above thickener in bFGF and dissolving it in a solution to give a solution having a predetermined viscosity. The ratio of bFGF to the total formulation is preferably about 0.0001 to 20% by weight, more preferably about 0.001 to 10% by weight, and most preferably about 0.01 to 1% by weight, as described above. BFGF is blended in such a ratio. Moreover, water can be preferably used as the solution. The use ratio of the thickener relative to the whole preparation varies depending on the type of thickener used, but can be determined within a range showing a viscosity of about 20 to 25,000 mPa · s in the solution state. For example, when HPC having a molecular weight of about 110,000 to 150,000 is used as the thickener, the thickener is dissolved in the solution so as to have a ratio of about 2 to 18% by weight, preferably about 3 to 10% by weight. Dissolve. If HPC having a molecular weight of about 250,000-400,000 is used, the thickener is dissolved in a solution of about 1 to 9% by weight, preferably about 2 to 6% by weight. Dissolve in

  In order to prepare the dental viscous preparation of the present invention, for example, an aqueous solution of bFGF is added to and mixed with powdered HPC, or an HPC viscous aqueous solution is obtained by dissolving HPC in water. Can be appropriately prepared as necessary using a method such as mixing an aqueous solution of bFGF. Specific methods for preparation are specifically described in the following examples, but are not limited thereto, and can be appropriately prepared within the scope of technical common knowledge in the art. Furthermore, the dental viscous preparation of the present invention prepared as described above can be lyophilized in order to ensure the long-term stability of bFGF and re-prepared by adding water at the time of use. is there. In addition, bFGF may be stored in a freeze-dried state and prepared by adding a viscous aqueous solution of HPC at the time of use.

  Therefore, the present invention also provides a kit for preparing the dental viscous preparation of the present invention, which comprises bFGF, a thickener, an inert and nontoxic additive if necessary, and a solution. And a method for preparing the dental viscous preparation of the present invention, which comprises dissolving bFGF, a thickener and, if necessary, an inert and non-toxic additive in a solution. Also related.

  In addition, since the dental viscous preparation of the present invention needs to be in a sterile state depending on the application method, the bFGF solution is preliminarily sterilized by filtration or the HPC powder is sterilized by radiation or dry. Aseptic conditions can be ensured by heat sterilization or by autoclaving the HPC viscous liquid.

  The viscous dental preparation of the present invention prepared by the above method can be directly administered to affected areas of various periodontal diseases by the same method as ointment, gel, pasta and liquid. For example, when an appropriate amount of a viscous preparation is taken with a 2 ml syringe attached with a syringe needle having a thickness of about 18 G and is administered widely and in large quantities to the affected area, the needle is administered with 18 G as it is. Moreover, when administering to a small gap | interval like a periodontal pocket, it can attach to the injection needle of about 26G, and can also administer. It is also possible to pre-fill the reservoir part of a kit product such as a simple injection device and administer it.

  It is also possible to apply directly to the affected area or separately on the spatula. In addition, it is possible to take a necessary amount from a pressurized metering pump or the like and apply it directly to the affected area or separately with a spatula or the like.

  The dosage of the dental viscous preparation of the present invention can be appropriately changed depending on the type of periodontal disease to be applied, severity, diseased range, patient sex, body weight, etc. In this case, it is preferable to apply a preparation in such an amount that about 0.1 to 3000 μg, preferably 1 to 1500 μg of bFGF is applied to the affected area by a single administration.

  As described above, the viscous preparation for dental use of the present invention is a restoration of periodontal tissue after periodontal disease and extraction of cysts or oral cancer as described above, promotion of colonization of the implant material, dentin deficient due to caries It can be applied for the purpose of treatment or prevention of periodontal diseases such as regeneration of cancer. For example, in the case of periodontal disease, it can be administered directly to the affected area, but when the root surface is exposed in the flap operation, the viscous dental preparation of the present invention is applied to, or injected into, the exposed surface. The frequency of administration varies depending on the type and severity of periodontal disease, but for example, when used in flap surgery for periodontal disease, this preparation is used once because the affected area is sutured after administration to the affected area such as the root surface. It is only administered.

  Hereinafter, the dental viscous preparation of the present invention will be described in more detail, but the present invention is not limited thereto. In addition, trafermin (genetical recombination) was used as human bFGF used in the following Examples and Test Examples.

Example 1
HPC (HPC-H (Nippon Soda Co., Ltd.), 15.0 g) was gradually added to 485 ml of water, and stirring was continued until the particles were completely dispersed and dissolved to obtain an HPC viscous liquid. After dispensing 2 ml each into an ampule, it was sealed and autoclaved. The obtained HPC viscous liquid had a viscosity of 10082.0 mPa · s (measured using an E-type viscometer at 25 ° C., and in the following Examples and Test Examples, there was no particular notice. As long as the viscosity was measured under the same conditions as in Example 1). Separately, citrate / sucrose buffer (pH 5.1, 1.0 ml) containing 0.89 or 2.67 mg / ml human bFGF, respectively, was sterilized by filtration and lyophilized in vials. To these freeze-dried products, the above-mentioned sterilized HPC viscous liquid (1.0 ml) was added, stirred and subjected to stationary defoaming to obtain a viscous dental preparation of the present invention (respectively formulation examples 1a ( 0.89 mg / ml), formulation example 1b (2.67 mg / ml)).

Example 2
HPC (HPC-H (Nippon Soda), 3.0 g) and 9.0 g of sucrose were gradually added to 87 ml of water, and stirring was continued until the particles were completely dispersed and dissolved to obtain an HPC viscous liquid. . While cooling and stirring this HPC viscous liquid, citrate buffer solution (pH 5.1, 1.0 ml) containing 10.1 mg / ml human bFGF was gradually added, and stirred until uniform. A viscous dental preparation of the present invention was obtained.

Example 3
Citrate / sucrose buffer (pH 5.1, 1.0 ml) containing 0.89, 2.67, or 8.00 mg / ml human bFGF was sterilized by filtration and lyophilized in vials. After adding 1 ml of water for injection to this lyophilized product and dissolving, HPC (HPC-H (manufactured by Nippon Soda Co., Ltd.), 30 mg) was gradually added and dissolved to obtain the viscous dental preparation of the present invention.

Example 4
Citrate / sucrose buffer solution (pH 5.1, 1.0 ml) containing 0.89, 2.67, or 8.00 mg / ml human bFGF was sterilized by filtration, and HPC (HPC-H (Nippon Soda) And 30 mg) were gradually added and dissolved, and then lyophilized in a vial. Water (1 ml) was added to the lyophilized product to obtain a viscous dental preparation of the present invention.

Example 5
Citrate / sucrose buffer (pH 5.1, 1.0 ml) containing 0.89, 2.67, or 8.00 mg / ml human bFGF was sterilized by filtration and lyophilized in vials. Separately, HPC (HPC-H (manufactured by Nippon Soda), 30 mg) was gradually dissolved in water (1 ml) and then freeze-dried in a vial. Water (0.5 ml each) was added to these lyophilized products to dissolve them, and both were mixed to obtain the viscous dental preparation of the present invention.

Example 6
Citrate / sucrose buffer solution (pH 5.1, 1.0 ml) containing 0.89, 2.67, or 8.00 mg / ml human bFGF was sterilized by filtration, and HPC (HPC-H (Nippon Soda) And 30 mg) were gradually added and dissolved to obtain a viscous dental preparation of the present invention.

Example 7
HPC (HPC-H (manufactured by Nippon Soda Co., Ltd.), 60 mg) was dissolved by adding water (1 ml), and this was sterilized by filtration using a citrate / sucrose buffer solution containing 5.34 mg / ml human bFGF ( pH 5.1, 1.0 ml) and mixed to obtain the viscous dental preparation of the present invention.

Example 8
HPC (HPC-H (manufactured by Nippon Soda), 30 mg) was gradually dissolved in water (1 ml) and then freeze-dried in a vial. This lyophilized product was dissolved by adding citrate / sucrose buffer (pH 5.1, 1.0 ml) containing 0.89, 2.67, or 8.00 mg / ml human bFGF sterilized by filtration. The viscous dental preparation of the present invention was obtained.

Example 9
HPC (HPC-H (manufactured by Nippon Soda), 60 mg) was gradually dissolved in water (1 ml) and then freeze-dried in a vial. A citrate / sucrose buffer solution (pH 5.1) containing 0.89, 2.67, or 8.00 mg / ml human bFGF, which was dissolved by adding water (1 ml) to the lyophilized product and sterilized by filtration. 1.0 ml) was added and mixed to obtain the dental viscous preparation of the present invention.

Test example 1
The stability of bFGF in the viscous dental preparation of the present invention was examined.
The preparations (1a, 1b) obtained in Example 1 were stored in a thermostatic chamber at 25 ° C., and the residual rate of bFGF was measured over time by the HPLC method. The results are shown in Table 1.

  From the results shown in Table 1, it was confirmed that the viscous dental preparation of the present invention stably retained bFGF even after 42 hours of preparation.

Test example 2
Using a Franz-type diffusion cell, the drug release property of the preparation (1b) obtained in Example 1 was controlled using an aqueous solution of bFGF (bFGF concentration: 0.267% by weight) as a control. The bFGF release rate was examined. The amount of bFGF in the receptor phase passing through the cellulose membrane was quantified with time by the HPLC method to determine the bFGF release rate. Citrate / sucrose buffer was used as the receptor solution. The results are shown in FIG.
According to the results shown in FIG. 1, the dental viscous preparation of the present invention showed a tendency to locally store bFGF for a longer time than the bFGF aqueous solution, and showed a pattern of releasing bFGF at a constant rate for a long time.

Test example 3
The dental viscous preparation of the present invention containing ¹²⁵ I-labeled bFGF (bFGF concentration: 0.97 mg / ml; HPC concentration: 3%; viscosity) in the vicinity of the ribs of the left hind limb of SD male rats (7 weeks old) : 10423 mPa · s) or ¹²⁵ I-labeled bFGF aqueous solution was intramuscularly administered (50 μl). The dose of bFGF was 48.52 μg per rat and the radiolabeled bFGF was 264.29 kBq per mouse. ¹²⁵ I-labeled bFGF at the administration site was measured 15 minutes, 30 minutes and 6 hours after administration. The radioactivity residual rate in the administered tissue is shown in FIG. Each value represents the mean ± standard deviation of 3 cases.
According to the results shown in FIG. 2, when the dental viscous preparation of the present invention is administered intramuscularly, the transfer of bFGF into the blood is slower than when the bFGF aqueous solution is administered, and the viscous preparation of the present invention is administered. In the rat, 90.6% of the radiolabeled bFGF remained at the administration site even after 15 minutes from the administration, and the administration of the preparation of the present invention was more effective than the administration of the bFGF aqueous solution. The residual rate of bFGF at the site was significantly high (0.01 <p ≦ 0.05, Student's t test). In addition, the residual ratio of bFGF at the administration site was higher in the preparation of the present invention than in the aqueous solution until 6 hours after administration.

Test example 4
Using a ¹²⁵ I-labeled bFGF having a specific activity of about 25 kBq / μg, 50 μl of the dental viscous preparation of the present invention or ¹²⁵ I-labeled bFGF aqueous solution having the composition shown in Table 2 below at the defect site of the right mandible of the rabbit. And the residual rate of ¹²⁵ I-labeled bFGF 6 hours after the administration was measured.

Specifically, the rabbit was kept under the stomach under Nembutal anesthesia (approx. 3 ml of 50 mg / ml solution), and locally anesthetized with xylocaine (approx. 1 ml of approximately 20 mg / ml solution). Then, the gingiva was incised along the right mandible, the periosteum was peeled off, and a two-wall defect was created in the mandibular incisor of the right mandible (buccal tongue width: about 4 mm; near centrifugal width: about 8 mm; Depth: about 4 mm). After hemostasis, 50 μl of the viscous dental preparation of the present invention or ¹²⁵ I-labeled bFGF aqueous solution was administered to the defect site of the right mandible, and rested for 30 seconds, and then the incised gingiva was placed on the defect site and sutured. Six hours after administration, the whole blood was collected, and the right mandible (from the right incisor including the defect site to the front of the anterior molar) and the incised and sutured gingiva were excised, and the radioactivity was measured with a γ counter. The residual rate (%) of ¹²⁵ I-labeled bFGF 6 hours after administration compared to immediately after administration is shown in Table 3 and shown in FIG.

  From the above results, it can be seen that, when the viscous preparation of the present invention is administered, bFGF remains at a high concentration at the administration site, particularly in the right gingiva even after 6 hours of administration, compared with the case where the bFGF aqueous solution is administered. It was recognized that the residual rate was higher as the HPC concentration contained in the viscous preparation of the present invention was higher. From these results, it was shown that the viscous preparation of the present invention leaves bFGF at a high concentration at the administration site for a long time after administration, as compared with the bFGF aqueous solution.

  The viscous dental preparation of the present invention contains basic fibroblast growth factor (bFGF) as an active ingredient and further has a certain viscosity by containing a thickener. As a result, the active ingredient bFGF is stably maintained physicochemically, and when applied to the affected area as a treatment for various periodontal diseases such as periodontal disease, it can be uniformly applied to the affected area. BFGF contained in the preparation is stably released to the affected area by storing the applied preparation for a relatively long time without running off from the application site, resulting in excellent therapeutic effects. Is obtained. In addition, since the preparation of the present invention has fluidity, it can cope with irregularities and gaps in the diseased part and can be administered accurately.

FIG. 1 is a diagram showing a release curve of bFGF from the viscous dental preparation of the present invention and an aqueous bFGF solution. FIG. 2 is a graph showing the residual rate of ¹²⁵ I-labeled bFGF in tissue after intramuscular administration of the dental viscous preparation of the present invention and bFGF aqueous solution to rats. FIG. 3 is a diagram showing the residual rate (%) of ¹²⁵ I-labeled bFGF 6 hours after administration compared to immediately after administration when the dental viscous preparation of the present invention and bFGF aqueous solution are administered to a rabbit mandible defect site. .

Claims (8)

  A viscous dental preparation containing basic fibroblast growth factor (bFGF) as an active ingredient and further containing a thickener.   Thickener is hydroxypropylcellulose, sodium alginate, propylene glycol alginate, carboxyvinyl polymer, carmellose sodium, hyaluronic acid, sodium hyaluronate, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, polyacrylic acid, polyacrylic acid The dental viscous preparation according to claim 1, which is at least one selected from the group consisting of sodium, partially neutralized polyacrylic acid, polyvinyl alcohol, methylcellulose, xanthan gum, chondroitin sulfate, and sodium chondroitin sulfate. .   The dental viscous preparation according to claim 1, wherein the thickener is hydroxypropylcellulose.   The dental viscous preparation according to any one of claims 1 to 3, which is used for treatment of periodontal disease.   The dental viscous preparation according to any one of claims 1 to 4, wherein the bFGF content is 0.0001 to 20% by weight based on the total weight of the preparation.   A kit for preparing the dental viscous preparation according to any one of claims 1 to 5, wherein bFGF, a thickener, and if necessary, an inert and non-toxic additive A kit containing an agent and a solution.   A method for preparing a viscous dental preparation according to any one of claims 1 to 5, comprising bFGF, a thickener and, if necessary, an inert and non-toxic additive. Is dissolved in a dissolving solution.   The method according to claim 7, wherein the solution is water.

Images